770-729-2992
Fighting the COVID-19 pandemic requires an arsenal of research tools and reagents. RayBiotech provides the most complete and comprehensive range of products and services to support your efforts in SARS-CoV-2 research and development of therapies and vaccines.
For researchers and health professionals needing lab facilities or additional expertise, RayBiotech offers contract research services to help reach your objectives faster. The symbol indicates products for which we offer full testing or custom service.
COVID-19 Collaborations: Collaborate with RayBiotech to advance COVID-19 research.
Antibody screening has important public health uses in determining immunity to and prevalence of COVID-19, as well as identifying who has been infected and evaluating potential blood based therapeutics. Detect IgG, IgM, and IgA antibodies to SARS-CoV-2 N and S1 RBD proteins in serum, saliva, and dried blood samples using the indirect ELISA kits.
The spike protein (S-protein) and nucleocapsid protein (N-protein) are encoded by all coronaviruses, including SARS-CoV-2 that was first detected in Wuhan City, China, in December 2019. Both recombinant forms of these proteins are now available from RayBiotech to advance infectious disease research.
Monoclonal & Polyclonal Antibodies to SARS-CoV-2
Frequently referred to as "synthetic antibodies", aptamers are single stranded DNA molecules which can specifically recognize and bind to the targeted protein. Multiple modifications available. Aptamer selection was done against recombinant SARS-CoV-2 protein (cat# 230-30164).
RayBiotech's innovative PCR kits allow rapid, convenient detection of SARS-CoV-2 nucleic acids. Our protocols offer unique advantages, such as enabling the researcher to skip laborious RNA extraction, or to avoid PCR machines entirely, and detect the virus by visual color inspection.
Different sample types from COVID-19 patients, including serum/plasma, PBMCs, dried blood spots, & more. Serum/plasma from non-COVID-19 patients also available.
Saliva and dried blood sample collection kits for RNA, DNA, Antibody and Protein analysis in normal (non-COVID-19) and COVID-19 samples.
The entry of the SARS-CoV-2 virus into host cell is mediated by an interaction between the Spike (S) protein’s receptor binding domain (RBD) on the surface of the viral particle and the Angiotensin I Converting Enzyme 2 (ACE2) receptor on the human cell surface. As such, this binding event is a biological target for COVID-19 therapies. The RayBio® COVID-19 Spike-ACE2 binding assay kit allows the researcher to rapidly screen and identify small molecules, antibodies, or other biological molecules that potentially interfere with the formation of the S-ACE2 complex.
Sandwich ELISA kits for detecting N- and S- proteins to SARS-CoV-2. Also offered is a sandwich ELISA for Human ACE2, an endogenous membrane protein that enables COVID-19 infection. Indirect ELISAs for IgG, IgM, and IgA antibodies to SARS-CoV-2 can be found in the above 'Antibody Testing' section.
Semi-quantitative detection of IgM and IgG antibodies in serum or plasma to the SARS-CoV-2 (COVID-19) spike (S) protein.
Name | Catalog # | CAS # | Target Candidate |
---|---|---|---|
Arbidol HCl | 331-11756 | 131707-23-8 | Viral spike glycoprotein for binding to host cell receptor ACE2 |
Ritonavir | 331-11642 | 155213-67-5 | HIV Protease |
Lopinavir | 331-11643 | 192725-17-0 | Coronavirus main protease 3CLpro |
Darunavir | 331-11645 | 206361-99-1 | HIV Protease |
Ribavirin | 331-10301 | 36791-04-5 | RNA-dependent RNA polymerase |
Chloroquine diphosphate | 331-11962 | 54-05-7 | Malaria (endosome/ACE2) |
Nitazoxanide | 331-11871 | 55981-09-4 | Viral protein expression |
Camostat mesilate | 332-10779 | 59721-29-8 | Transmembrane protease, serine 2, primes S protein to facilitate its binding to ACE2 |
Hydroxychloroquine Sulfate | 331-21357 | 747-36-4 | Malaria (endosome/ACE2) |
Baricitinib Phosphate | 332-10769 | 1187595-84-1 | JAK kinase that regulate the inflammatory processes |
Cell-based neutralization service to study neutralizing antibodies and Spike-ACE2 inhibitors using a SARS-CoV-2 pseudovirus.